JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

Начало・Списък с акции・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Затворен

СекторЗдравеопазване

16.54 -4.12

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

16.42

Максимум

17.18

Ключови измерители
By Trading Economics
Приходи	4.8M -36M
Продажби	6.1M 116M
Марж на печалбата	-30.977
Служители	1,869
EBITDA	24M -31M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+126.28% upside

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-1.1B 2B
Предишно отваряне	20.66
Предишно затваряне	16.54

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

28.13 / 31.12 Подкрепа & съпротива

Zai Lab Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

30.01.2026 г., 20:14 ч. UTC

Придобивния, сливания и поглъщания

Reddy Ice to Buy Arctic Glacier, DOJ Requires Certain Divestitures

30.01.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- WSJ

30.01.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Nvidia, OpenAI in Talks to Revise Nature of Broader Partnership, Sources Say -- WSJ

30.01.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Nvidia CEO Jensen Huang Has Privately Told Colleagues That Deal Is Non-Binding, Sources Say -- WSJ

30.01.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Nvidia's Huang Has Privately Criticized OpenAI's Business Strategy, Sources Say -- WSJ

30.01.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

OpenAI, Nvidia Deal Talks Stalled in Recent Months, Sources Say -- WSJ

30.01.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Nvidia's Huang Expressed Concerns Over Competition OpenAI Faces From Anthropic, Google, Sources Say -- WSJ

30.01.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Nvidia Weighing Equity Investment of Tens of Billions of Dollars Into OpenAI, Sources Say -- WSJ

30.01.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Negotiations Over $100B OpenAI, Nvidia Deal Stall, Sources Say -- WSJ

30.01.2026 г., 23:41 ч. UTC

Пазарно говорене

Deckers Outdoor Seen as Undervalued -- Market Talk

30.01.2026 г., 23:12 ч. UTC

Придобивния, сливания и поглъщания

Supreme Court of British Columbia Approves Fortescue Purchase of Alta Copper

30.01.2026 г., 22:20 ч. UTC

Печалби

Verizon Posts Strong Subscriber Gains Under New CEO -- WSJ

30.01.2026 г., 22:10 ч. UTC

Пазарно говорене

Disney CEO's Exit Plan Marks Abrupt End to Messy Succession -- Market Talk

30.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

30.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

30.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

30.01.2026 г., 21:42 ч. UTC

Печалби

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30.01.2026 г., 21:36 ч. UTC

Печалби

GE Aerospace and GE Vernova Issue Their Annual Reports. They Contain Messages for Investors. -- Barrons.com

30.01.2026 г., 21:33 ч. UTC

Печалби

Tesla Stock Rebounds From Earnings Dip. SpaceX Is Helping. -- Barrons.com

30.01.2026 г., 20:42 ч. UTC

Печалби

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30.01.2026 г., 20:37 ч. UTC

Придобивния, сливания и поглъщания

Why a Ruling Over CK Hutchison's Panama Canal Ports Matters -- and What's Next -- WSJ

30.01.2026 г., 20:20 ч. UTC

Пазарно говорене

Oil Posts Weekly Gains on U.S.-Iran Tensions -- Market Talk

30.01.2026 г., 20:13 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise on Weather-Driven Demand -- Market Talk

30.01.2026 г., 19:52 ч. UTC

Печалби

Visa and Amex Results Point to a Strong Holiday Season for Retailers -- Barrons.com

30.01.2026 г., 19:29 ч. UTC

Пазарно говорене

Печалби

KLA Guidance Only 'Tepid' as Memory Rally Favors Peers -- Market Talk

30.01.2026 г., 19:09 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

30.01.2026 г., 19:09 ч. UTC

Пазарно говорене

Next Canadian Inflation Release Pushed Back a Day to Not Clash With Holiday -- Market Talk

30.01.2026 г., 19:07 ч. UTC

Пазарно говорене

Canada Performing Well Below Economic Potential -- Market Talk

30.01.2026 г., 18:46 ч. UTC

Печалби

'All Boats Are Rising' in Data and Memory, Says Western Digital's CFO. Just Look at the Stocks. -- Barrons.com

30.01.2026 г., 18:34 ч. UTC

Печалби

Exxon, Chevron Post Slimmest Annual Profits Since 2021 -- 2nd Update

Сравнение с други в отрасъла

Ценова промяна

Zai Lab Ltd ADR Прогноза

Ценова цел

By TipRanks

126.28% нагоре

12-месечна прогноза

Среден 38.92 USD 126.28%

Висок 58 USD

Нисък 25.7 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Zai Lab Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Zai Lab Ltd ADR през последните 3 месеца.

Техническа оценка

By Trading Central

28.13 / 31.12Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.